The Latest Cardiac and Vascular News
BASKING RIDGE, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that Joseph Talamo, Chief Financial Officer (“CFO”), has tendered his resignation in […]
CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and our CRO’s are focused on completing enrollment of both of our Phase 3 MAESTRO clinical trials as rapidly as possible,” said Becky Taub, M.D., […]
SUNNYVALE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2020. “While the second quarter posed several challenges, we are pleased with […]
Westport, CT, Aug. 05, 2020 (GLOBE NEWSWIRE) — Dr. Sofia is an Inductee in the American Chemical Society Medicinal Chemistry Hall of Fame ViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), […]
ST. LOUIS, Aug. 06, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2020. “Stereotaxis responded to the challenges of COVID-19 with resilience, prudence and creativity. Despite a 21% year-over-year […]
ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 30, 2020. Recent Highlights OCS Heart FDA Advisory […]
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseases ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020 WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a […]
– Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, topline data expected Q4 2020 – Progressing first- or best-in-class drug candidates with liquidity position of ~$1.3bn as of June 30, 2020 SAN DIEGO, Aug. 5, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial […]
Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney disease on dialysis Maintains strong balance sheet with $204.8 million in cash, cash equivalents and short-term investments FREMONT, Calif., Aug. […]
WYNNEWOOD, Pa., Aug. 6, 2020 /PRNewswire/ — Lankenau Heart Institute, part of Main Line Health, has named Basel Ramlawi, MD, the System Chief of Cardiac Surgery for Main Line Health and co-director of the Lankenau Heart Institute. Dr. Ramlawi brings nearly 20 years of complex and minimally invasive cardiovascular surgical experience to his new […]
